Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic ... limiting generic competition and ensuring continued market exclusivity ...

Novo Nordisk, the maker of Ozempic and Wegovy, is predicted to lose billions in profits due to a minor billing error in ...